Key result
Antithrombotic therapy is linked to lower plasma TAT and PTF hypercoagulability markers in AF.
Why the study?
Atrial fibrillation predisposes patients to thrombosis, but identifying hypercoagulable states using molecular markers and the effect of antithrombotic therapy on these markers needed investigation.
Observational (n=83)
Associated marker reductions in AF support further study; should not yet change practice.
It is well known that atrial fibrillation (AF) is one of the most important diseases that predispose patients to thrombosis. We have attempted to identify patients with AF in the hypercoagulable state by measuring molecular markers such as thrombin—antithrombin III complex (TAT) and prothrombin fragment 1 + 2 (PTF) and determining the effect of antithrombotic therapy on these markers; 83 patients with AF were studied. Increased levels of plasma TAT and PTF were more frequently observed in patients with AF and associated mitral stenosis than in patients with AF alone. In cases of AF without mitral stenosis, plasma levels of TAT and PTF were significantly lower in those patients receiving antithrombotic agents (aspirin or warfarin) than in those receiving no antithrombotic agents. Furthermore, plasma levels of PTF were significantly lower in patients given warfarin than in those receiving aspirin. These results suggest that (1) patients with AF and mitral stenosis who are not given warfarin are in an extremely hypercoagulable state and (2) some patients with AF without mitral stenosis who are not given antithrombotic agents are also moderately hypercoagulable.In vivoactivation of blood coagulation was more effectively controlled in patients receiving warfarin than in those taking aspirin.
No takes yet. Share an insight, caveat, or question.
Asakura et al. (1992) conducted an observational in Atrial fibrillation (n=83). Antithrombotic therapy (warfarin or aspirin) vs. No antithrombotic therapy was evaluated on Plasma levels of thrombin-antithrombin III complex (TAT) and prothrombin fragment 1 + 2 (PTF). Among 83 patients with atrial fibrillation, antithrombotic therapy with warfarin or aspirin was associated with significantly lower plasma levels of hypercoagulability markers TAT and PTF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: